drugset / Trial / NCT04445337

Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients

NCT04445337

Phase 1 Terminated 1 enrolled University of Nebraska
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will establish the safety and efficacy of using stellate ganglion blocks in patients with acute respiratory distress syndrome (ARDS) due to COVID-19 disease.

Timeline

Start
2020-11-15
Primary completion
2021-10-01
Completion
2021-11-01

Drugs

EvaluationDrugModalityDoseRoute
Background Bupivacaine Other / unclassified 2 ml Other
Background Clonidine Other / unclassified 100 ug Other
Background Dexamethasone Small molecule 5 mg Other